Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Parkinson Disease”

274 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 274 results

Testing effectiveness (Phase 2)Study completedNCT02577523
What this trial is testing

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

Who this might be right for
Parkinson's Disease
NeuroDerm Ltd. 38
Large-scale testing (Phase 3)Study completedNCT00203164
What this trial is testing

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

Who this might be right for
Parkinson's Disease
Teva Branded Pharmaceutical Products R&D, Inc. 254
Testing effectiveness (Phase 2)Ended earlyNCT00607451
What this trial is testing

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

Who this might be right for
Levodopa-induced Dyskinesia
Neurim Pharmaceuticals Ltd. 8
Testing effectiveness (Phase 2)UnknownNCT00159172
What this trial is testing

Safety and Efficacy of Motor Cortex Stimulation in the Treatment of Advanced Parkinson Disease

Who this might be right for
Parkinson Disease
Assistance Publique - Hôpitaux de Paris 10
Large-scale testing (Phase 3)Study completedNCT00577460
What this trial is testing

Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD

Who this might be right for
Parkinson Disease
Boehringer Ingelheim 391
Post-approval studies (Phase 4)Study completedNCT00141518
What this trial is testing

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

Who this might be right for
Advanced Idiopathic Parkinson's Disease
AbbVie (prior sponsor, Abbott) 77
Large-scale testing (Phase 3)Study completedNCT00660673
What this trial is testing

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Who this might be right for
Advanced Parkinson's Disease
AbbVie 262
Testing effectiveness (Phase 2)Study completedNCT02674061
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Who this might be right for
Ovarian Neoplasms
Merck Sharp & Dohme LLC 376
Large-scale testing (Phase 3)Study completedNCT00466167
What this trial is testing

Pivotal Study in Advanced Parkinsons Disease Patients

Who this might be right for
Parkinson Disease
Boehringer Ingelheim 517
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130
Testing effectiveness (Phase 2)Looking for participantsNCT05319730
What this trial is testing

Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 230
Early research (Phase 1)Study completedNCT02964013
What this trial is testing

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Who this might be right for
Neoplasms
Merck Sharp & Dohme LLC 474
Not applicableStudy completedNCT03189459
What this trial is testing

In-Home Care for Patients With Parkinson's Disease

Who this might be right for
Parkinson Disease
Rush University Medical Center 164
Not applicableStudy completedNCT02381444
What this trial is testing

Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy

Who this might be right for
Parkinson's Disease (PD)
AbbVie 136
Not applicableStudy completedNCT03317509
What this trial is testing

The Effect of High Frequency rTMS on Advancing Parkinson's Disease With Dysphagia

Who this might be right for
Advanced Parkinson's With Dysphagia
Assiut University 30
Testing effectiveness (Phase 2)Study completedNCT00148512
What this trial is testing

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

Who this might be right for
Parkinson Disease
Boehringer Ingelheim 254
Testing effectiveness (Phase 2)Active Not RecruitingNCT02628067
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Who this might be right for
Advanced CancerAnal CarcinomaAnal Cancer+22 more
Merck Sharp & Dohme LLC 1,609
Large-scale testing (Phase 3)Study completedNCT01631825
What this trial is testing

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Who this might be right for
Parkinson's Disease
Otsuka Pharmaceutical Co., Ltd. 321
Large-scale testing (Phase 3)Study completedNCT03898180
What this trial is testing

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Who this might be right for
Urothelial Carcinoma
Merck Sharp & Dohme LLC 505
Testing effectiveness (Phase 2)Study completedNCT04165096
What this trial is testing

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 128
Load More Results